SecBot SecBot
PRESS-RELEASE ·Filed Apr 3, 2026

SYRE

Spyre Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed7mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

Monitor for additional equity grants or insider activity, especially given the activist context; while this filing is routine, a pattern of equity inducements could signal talent retention challenges or dilutive practices.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$48.98
T+0 close · Apr 3, 2026 · via day close
Latest settled
+81.48%
T+60 · $88.89
Vs SPY
+68.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $48.98entry
  2. T+1 · 7mo ago +4.53%α +4.47% · $51.20
  3. T+5 · 7mo ago +29.18%α +25.04% · $63.27
  4. T+20 · 7mo ago +41.14%α +32.16% · $69.13
  5. T+60 · 5mo ago +81.48%α +68.01% · $88.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spyre Therapeutics granted stock options to purchase 70,200 shares to five non-executive employees as inducement awards under its 2018 Equity Inducement Plan. The options have a 10-year term, an exercise price of $48.90, and vest over four years, with one-fourth vesting on the first anniversary and monthly thereafter, subject to continued service.

Key Facts

  • Spyre granted stock options for 70,200 shares to five non-executive employees.
  • Options were granted under Nasdaq Listing Rule 5635(c)(4) as inducement awards.
  • Exercise price is $48.90, equal to the closing price on April 1, 2026.
  • Options have a 10-year term and vest 25% on first anniversary, then 1/48th monthly over next 36 months.
  • Grants were material to employment acceptances.

Financial Impact

Minimal near-term financial impact; total potential dilution of 70,200 shares (~0.19% of $3.7B market cap at $48.90).

dilutionshare_countcompensation_expense

Risk Factors

  • Potential for incremental shareholder dilution if future inducement grants scale significantly.
  • Activist scrutiny may increase if governance or compensation practices are perceived as excessive.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3268133

Track record

36 reports on SYRE

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026